Greenman Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.51 Cr
as on 24-10-2024
- Revenue 29.77%
(FY 2023)
- Profit 40.09%
(FY 2023)
- Ebitda 153.96%
(FY 2023)
- Net Worth 47.66%
(FY 2023)
- Total Assets -5.52%
(FY 2023)
About Greenman Life Science
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.51 Cr.
Dilipsinh Vaghela, Illyashbhai Mir, Zalamsinh Dodiya, and One other member serve as directors at the Company.
- CIN/LLPIN
U24111GJ2018PTC101031
- Company No.
101031
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Greenman Life Science Private Limited offer?
Greenman Life Science Private Limited offers a wide range of products and services, including Insecticides and Pesticides, Selective Herbicide, Termiticide, Pest Control Chemicals, Acaricide, Fungicides, Non Selective Herbicide, Insecticides.
Who are the key members and board of directors at Greenman Life Science?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilipsinh Vaghela  | Director | 24-Jun-2020 | Current |
| Illyashbhai Mir | Director | 28-Feb-2018 | Current |
| Zalamsinh Dodiya | Director | 28-Feb-2018 | Current |
| Naushir Vahora | Whole-Time Director | 11-Feb-2019 | Current |
Financial Performance of Greenman Life Science.
Greenman Life Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.77% increase. The company also saw a substantial improvement in profitability, with a 40.09% increase in profit. The company's net worth Soared by an impressive increase of 47.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Greenman Life Science?
In 2023, Greenman Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Sep 2023 | ₹1.01 Cr | Open |
Others Creation Date: 15 Feb 2022 | ₹5.00 M | Open |
How Many Employees Work at Greenman Life Science?
Unlock and access historical data on people associated with Greenman Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Greenman Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Greenman Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
